Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Abstract

Lenvatinib plus pembrolizumab showed promising antitumor activity in patients with advanced endometrial carcinoma who have experienced disease progression after prior systemic therapy, regardless of tumor MSI status. The combination therapy had a manageable toxicity profile.